United States : Bio-Rad Gains Additional U.S. FDA Clearances for Blood Typing Products, Expanding its Offering for the Blood Testing Market.
Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rads IH-System Gel Reagents for manual blood typing methods.
With the addition of the IH-Centrifuge L and IH-Incubator L to Bio-Rads portfolio of blood typing platforms, transfusion medicine laboratories of any size can standardize automated and manual typing with one method and supplier. The unique design of the two instruments maximizes efficiency and space in the laboratory by accommodating both conventional tube and gel blood typing.
We are pleased to receive FDA clearance for our IH-Incubator L and IH-Centrifuge L instruments for use with our IH-System Gel Reagents and look forward to extending our reach in the U.S. transfusion medicine market, said John Hertia, Bio-Rad Executive Vice President and President, Clinical Diagnostics Group. "This addition rounds out our offering, specifically benefitting smaller laboratories that use manual methods to test blood.
Bio-Rad provides a wide variety of platforms, reagents, data management, and connectivity solutions to address different blood typing needs, offering efficient and reliable results for blood grouping, phenotyping, crossmatching, antibody screening and identification, direct antiglobulin tests, and single antigen typing.
[c] 2017 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 30, 2018|
|Previous Article:||Saudi Arabia : Stc Announces Agreement With Corning Incorporated to Supply Fiber to Home Solutions.|
|Next Article:||United States : Deputy Secretary Sullivan Travels to Iraq.|